Lam Research Receives IBD Rating Upgrade, Forms Base

Lam Research (LRCX) saw an improvement in its IBD SmartSelect Composite Rating Thursday, from 94 to 96.


The new rating shows the stock is outpacing 96% of all stocks when it comes to the most important stock-picking criteria. The top-performing stocks tend to have a 95 or better grade as they launch a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch.

Lam Research is currently forming a flat base, with a 673.90 entry. Look for the stock to break out in heavy trade at least 40% above average. Keep in mind that it’s a later-stage base, which makes it a riskier entry point.

See How IBD Helps You Make More Money In Stocks


Lam Research stock earns a 95 EPS Rating, meaning its recent quarterly and annual earnings growth is outpacing 95% of all stocks.

Its Accumulation/Distribution Rating of B- shows moderate buying by institutional investors over the last 13 weeks.

In Q3, the company reported 88% EPS growth. Top line growth climbed 54%, up from 34% in the prior quarter. That marks one quarter of accelerating revenue gains. Lam’s next quarterly report is expected on or around July 29.

Lam Research earns the No. 5 rank among its peers in the Electronics-Semiconductor Equipment industry group. ASML Holdings (ASML) is the No. 1-ranked stock within the group.


Which Companies Are Now Outperforming 95% Of All Stocks?

See Which Stocks Just Came On — And Off — IBD’s Top Stock Lists

Identify Bases And Buy Points With Pattern Recognition From MarketSmith

Most Related Links :
todayprimenews Governmental News Finance News

Source link

Back to top button